Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:RARE
Date2/2014
Raised$126M
Post IPO Valuation

General Information

Offices

Novato, USA
77 Digital Drive
Suite 210
Novato, CA, 94949
USA

People

Chairman of the Board
President & CEO
SVP Finance & CFO
Director
Chief Business Officer and Senior Vice President

Funding

Tags

Ultragenyx Pharmaceutical

Ultragenyx™ develops therapeutics for rare diseases, sometimes referred to as Orphan products. Founded in 2010, the company is led by Emil Kakkis, M.D., Ph.D., former CMO of BioMarin Pharmaceutical. Efficient and effective development strategies are essential for success in the rare disease space, in which information may be incomplete or ambiguous, and few development precedents exist. The management team’s experience in selecting and developing products with clear mechanisms of action for untreated rare diseases will help Ultragenyx create life-changing therapeutics by leveraging existing yet undeveloped science for these little-known indications.

Recent Milestones

Videos

Screenshots

Stock Price

Sources

  1. Ultragenyx Pharmaceutical Closes $45M Series A Financing (finsmes.com) [edit]
  2. Ultragenyx raises $15 million (bizjournals.com) [edit]
  3. Ultragenyx Raises $75 Million in Oversubscribed Crossover Financing (globenewswire.com) [edit]
Edit This Page
Last Edited 3/14/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy